

Dosimetric Outcomes of Three Dimensional Conformal Radiation Therapy and Intensity Modulated Radiation Therapy Coplanar Plans for Patients with Glioblastoma Multiforme (GBM)

Sajad A Rather¹, Ajaz A Khan², Nayak B Gull³, M Mohibul Haq⁴, Mudasir A Shah⁵, Misba H Baba⁶, Mohsin R Khan⁷, Nazir A Dar⁸

Author's Affiliation: ¹Assistant Professor, ²Medical Physicist, ³Senior Resident, ⁴Professor, ⁵⁻⁷Research Officer, ⁸Statistician, ^{1,2,4,5,6,7}Department of Radiological Physics and Bio-Engineering, ^{3,8}Department of Radiation Oncology, Sher-i-Kashmir Institute of Medical Sciences, Srinagar 190011, India.

Corresponding Author: Sajad Ahmad Rather, Assistant Professor, Department of Radiological Physics and Bio-Engineering, Sher-i-Kashmir Institute of Medical Sciences, Srinagar 190011, India.

E-mail: sajadahmadrather56@gmail.com

How to cite this article:

Sajad A. Rather, Ajaz A. Khan, Nayak B. Gull et. al. Dosimetric Outcomes of Three Dimensional Conformal Radiation therapy and Intensity Modulated Radiation therapy coplanar Plans for Patients with Glioblastoma Multiforme (GBM). Indian J Canc Educ Res 2020;8(2):9-14.

Abstract

The aim of the present study is to evaluate the dosimetric analysis of doses received by planning target volume and organs at risks by using intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) techniques in patients treated for glioblastoma multiforme. A total of ten patients underwent computed tomography treatment planning in conjunction with magnetic resonance imaging fusion. Prescription dose and normal-tissue constraints were identical for the 3DCRT and IMRT plans. All the Patients were treated on Clinac DHX Linear Accelerator. The prescribed dose was 60 Gy delivered at 2.0 Gy per fraction using 6 MV photons. The tolerance level for maximum dose was 7.0 Gy for lenses and 54.0 Gy for brain stem, optical chiasm and optical nerves as per RTOG criteria. The Target volumes, organ at risk (OAR), dose volume constraints were used for planning. Cumulative dose volume histogram of target volumes and organ at risk (OAR), normal brain tissue integral dose, target coverage, target homogeneity, target conformity, and normal tissue sparing with 3DCRT and IMRT planning were compared. Statistical analysis was performed to determine the differences. A statistically significant difference between 3DCRT and IMRT and in the mean dose to the PTV ($p < 0.519$) has been observed. The mean value of the PTV was 61.04 ± 1.152 in 3DCRT and 60.72 ± 1.005 in IMRT. The maximum dose to the PTV in 3DCRT (64.26 ± 2.36) and in IMRT (62.95 ± 2.33) had a lower maximum dose to the PTV ($p = 0.228$). This result indicates that IMRT was better than 3DCRT. The average minimum dose in IMRT was (46.80 ± 3.89) compared to (49.06 ± 4.98) in 3DCRT, ($p = 0.285$). The dose to 95% of the PTV was (57.73 ± 1.55) in IMRT to (58.20 ± 0.97) in 3DCRT, ($p = 0.423$). Conformity index (CI) was approximately equal in both modalities with an average value of 0.962 ± 0.041 in IMRT compared to (0.969 ± 0.039) in 3DCRT, ($p = 0.481$). The average homogeneity index (HI) in IMRT was 0.187 ± 0.176 and 0.099 ± 0.050 in 3DCRT, ($p = 0.165$). Therefore, IMRT achieved an improvement in HI. Target coverage index (TCI) in IMRT was 0.7213 ± 0.2050 and 0.5970 ± 0.194 in 3DCRT. The IMRT plan yielded superior target coverage and reduced radiation dose to the brain, brainstem, and optic chiasm. With the availability of new cancer imaging tools and more effective systemic agents, IMRT may be used to intensify tumor doses while minimizing toxicity, therefore potentially improving outcomes in patients with high-grade glioma.

Keywords: Glioblastoma multiforme (GBM); Intensity modulated radiation therapy (IMRT); Three dimensional conformal radiation therapy (3DCRT).

Introduction

Treatment for malignant gliomas typically requires a combined approach that includes surgery, radiotherapy and chemotherapy. Radiotherapy

is an important adjuvant treatment for malignant gliomas. Intensity-modulated radiotherapy (IMRT) has been demonstrated to be superior to three-dimensional conformal radiotherapy (3D-CRT) in patients with malignant gliomas.¹⁻³ The treatment of malignant gliomas after surgery has been

reported to significantly prolong patient survival.⁴⁻⁶ With the introduction of modern techniques like Three Dimensional Conformal Radiation therapy (3D CRT) and Intensity-Modulated, the use of Radiation therapy (IMRT) is increasing in clinical practice.⁷⁻⁹ Modern radiotherapy techniques such as 3D CRT and IMRT significantly increase the dose to the tumor and reduce the dose to the normal tissue.¹⁰⁻¹²

Intensity modulated radiation therapy (IMRT) uses computed tomography based planning and delivery of radiation, and with the help of TPS improves the dose to target, while minimizing doses to organs at risk (OAR), it can provide significantly better tumor target coverage and sparing of sensitive normal tissue compared with 3D CRT.¹³⁻¹⁴ Such modern techniques use modern medical imaging techniques, efficient dosimetric software, accurate patient positioning methods, stringent verification and quality control of procedures, which increases tumor control by boosting tumor dose, reducing morbidity and sparing healthy tissues.¹⁵ Three dimensional conformal radiation therapy uses computed tomography planning to generate 3D volumes of a patients' anatomy. In 3D CRT, multiple beams at various angles are projected towards target in such a way that the intended dose will be delivered to the target while relatively sparing critical structures. 3D CRT often produces unacceptable plans for concave or irregular targets that are close to critical structures.¹⁶ In Intensity modulated radiation therapy (IMRT) dynamic or static multileaf collimators are used for dose optimization and thus delivers highly conformal dose to target while sparing the surrounding normal structures. The multileaf collimator can be in a "dynamic" or "static" form. In the dynamic form, the leaves at each gantry position are swept across the target while the beam is on and their speed determines the radiation fluency. In static or segmental multileaf IMRT, each field consists of multiple segments with different intensities. These forms of IMRT are currently offered by most manufacturers of linear accelerators.¹⁷⁻¹⁹ Intensity modulated radiation therapy (IMRT) requires additional clinician input for delineating target volumes and more robust physics actions has to be performed. Assessment of the risks and benefits of IMRT is therefore important in determining its clinical utility.¹⁷ The dose-volume-histogram (DVH) is a common tool used in both IMRT and 3D CRT to evaluate dose conformity and homogeneity to target and at the same time this tool gives information about the dose received by the critical structures. DVHs do not provide spatial information such

as the location of the high- and low-dose regions ("hot" and "cold" spots) inside the volume of interest (VOI).¹⁸ Patient-specific quality assurance (QA) is used to verify the dose mapping given by the treatment planning system (TPS). Verification procedures for 3D conformal radiation therapy (3D CRT) and intensity-modulated radiotherapy (IMRT) are commonly performed for an individual patient.¹⁹

Materials and Methods

2.1. Planning Systems and Radiotherapy Machine

Clinac DHX was the linear accelerator used for present study. It has 40 pairs of multi leaf collimators, the width of each leaf when projected at the isocenter is 10 mm. This linear accelerator has two modes of treatment, photon mode and electron mode. In this study only photon mode with 6 MV energy is used. The treatment planning system was the external beam planning system of Eclipse (Varian Medical System) and the volume calculation used was the Anisotropic Analytical Algorithm (AAA).

2.2. Acquisition and Simulation

Planning CT scans were taken on Somatom Sensation Siemens CT Simulator with patients in supine position and immobilized with a three clamp orfit cast. Imaging acquisition protocol required a slice thickness of 3 mm in a multislice CT scanner, both immediately (within 15 s) and delayed, in other words, 10 min after injection of contrast. The images were then transferred to the Eclipse™ treatment planning system (v. 13.2, Varian Medical Systems, CA, USA). Planning CT images were fused with postoperative magnetic resonance (MR) images that were taken a few days before starting the radiation. The target and other OAR's were contoured following RTOG protocol. The gross tumor volume (GTV) included postoperative cavity and gross residual tumor seen on the CT images and fused MR images. The clinical target volume (CTV) includes 2.0 cm isotropic margin all around the GTV along with edema surrounding the tumor following anatomical boundaries. PTV was generated by giving a 0.5 cm symmetrical margin around the CTV. OARs, including the optic chiasm, right and left optic nerves, right and left temporal lobes, brain stem, right and left eye, right and left lens and right and left cochlea, were contoured.

Plans were optimized to deliver prescribed dose to more than 95% of PTV and maximum dose in the target volume not to exceed 107% of prescribed dose international commission on radiation units and measurements (ICRU): 50 and 62. Dose volume histograms were generated for qualitative and quantitative assessment of generated plans and evaluated for all the OARs before delivering treatment. Evaluation of dosimetric data was done, in other words, doses received by target volumes and OARs using Quantitative Analysis of Normal Tissue Effects in Clinics (QUANTEC). If the dose constraints of OARs were not met, depending on the location and burden of the tumor, we prioritized the OARs surrounding the tumor and plans were optimized accordingly, for example, for tumors close to or invading the left optic nerve, instead of under dosage, we have preferred treating till 60 Gy after prioritizing the right optic nerve to preserve vision. All 3D-CRT plans were analyzed in terms of PTV coverage, conformity index (CI), homogeneity index (HI) and OAR dose volume parameters, as per ICRU 83.

2.3. Conformal Planning

Treatment plans were created with 6 MV photons. All fields were shaped at the beam's eye view to encompass the PTV shape using multileaf collimator (MLC). The treatment target volume included the PTV and an additional 0.7-cm margin for beam penumbra in all directions. The treatment field's isocenter was positioned in the center of the PTV and the calculation point was taken at the treatment field's isocenter. Physical wedges (PW) and virtual wedges (VW) were used to modify the dose in the treatment plan and to perform dose homogeneity in PTV.

2.4. Inverse-Planned IMRT

Treatment plans were created for 6-MV photons with the same TPs with objective functions based on physical constraints. IMRT plans were generated using commercial inverse planning software. The beams are spread around the target with equispace and to avoid the opposing fields an odd numbers of the treatment fields were used.

2.5. Treatment Planning Evaluation Tools

The TPS used for this study (Eclipse 13.2) have many tools for qualitative and quantitative evaluation

of the treatment plans. The visual slice by slice review of the treatment plans using isodose lines distribution can be used as a qualitative evaluation for the treatment plans. The qualitative evaluation is important to know the location of the hot and cold areas in the treatment plans. The quantitative evaluation included the maximum, minimum, mean doses and DVHs. Dose Volume Histogram (DVH) was generated to evaluate the dose to the different structures in different treatment plans. For PTV, the parameters, D98%, D95% and D2% were used for plan evaluation, where D98% and D2% values are defined as the dose received by 98% and 2% of the PTV volume these two values are represented the maximum and minimum doses in the PTV, D95% is target volume covered by 95% of the prescribed dose, for OARs, the mean and maximum dose for brain stem, optic nerve and lenses were used for treatment plan evaluation.

2.6. Comparative evaluation of treatment plans

In this study, dosimetric analysis of 3D CRT and IMRT plans was performed for each of the 10 patients by both qualitative and quantitative measures. Isodose distribution was first compared visually on axial, sagittal and coronal slices for degree of conformity of the prescribed dose to the PTV and then for any inclusion of OAR within high dose and low dose levels. Specifically, we examined isodose lines from 5 Gy and up in our evaluation. Direct comparison was also made of the cumulative DVH curves for PTV, OAR, and non-target tissue. Integral dose to non-target brain tissue (Brain-PTV) was evaluated. Plan comparison was also made quantitatively by comparing DVH parameters and by computing and comparing relevant metrics for target coverage, target conformity, dose heterogeneity within the target, and critical normal tissue sparing. Target coverage was assessed by comparing the minimum and maximum doses to PTV (D_{min} and D_{max} respectively).

The dosimetric evaluation metrics used to compare the two plans, in terms of mean, maximum and minimum doses to PTV, were dose to 95% of PTV, Homogeneity Index (HI), Conformity Index (CI), Target Coverage Index (TCI) and Mean and maximum doses to critical organs and normal tissue. The dose to 95% of the PTV (D95%) was used to quantify PTV coverage. The homogeneity index (HI) was used to evaluate uniformity (homogeneity) of dose within the PTV and is calculated as

$$HI = \frac{D_{2\%} - D_{98\%}}{D_{50\%}} \quad (1)$$

Where $D_{2\%}$ and $D_{98\%}$ represent the doses to 2% and 98% of the PTV, respectively. For example, D_{98} indicates that at least 98% of the target volume receives this dose, and hence $D_{2\%}$ and $D_{98\%}$ are considered to be the maximum and minimum doses, respectively.

The conformity index (CI) was also calculated and can be defined as the degree of conformity of the plans, which is a ratio of the PTV receiving 95% of the prescribed dose divided by the volume of the PTV. A CI value approaching 1 indicates a higher degree of conformity.

$$CI = \frac{PTV_{95\%PD}}{V_{PTV}} \quad (2)$$

The target coverage index (TCI) accounts for the exact coverage of PTV in the treatment plan at the prescribed dose as shown below:

$$TCI = \frac{PTV_{PD}}{PTV} \quad (3)$$

Where PTV_{PD} is the PTV coverage at the prescribed dose (PD) and PTV is the volume of PTV. Target conformity index reports target dose coverage as a value between 0 and 1. A value of 1 indicates an ideal plan with target coverage by prescribed dose. However, a TCI value of 0 indicates the whole target volume is not covered by the prescribed dose [20-21].

Statistical Analysis

Statistical analysis was done using a paired two-tailed student's *t* test. The test was applied to calculate the difference between two means. A value of $p \leq 0.05$ was considered to be statistically significant.

Results

Differences were recorded between those patients who planned with 3D CRT and those who planned with IMTR. Thus one patient was selected to represent all other patients in this site for isodose distribution comparison, dose volume histogram (DVH) comparison, dosimetric results for the PTV and dosimetric results for the critical organs. DVHs figures include the PTV and critical organs for each modality and show the percentage of the total volume (y-axis) of each ROI receiving a specified dose (x-axis) in units of Gy.

3.1. Glioblastoma (GBM) Cancer

Ten patients whose diagnosis with GBM received 60 Gy per 30 fractions given once daily five days per week over a period of six weeks were included in this study. CT Scans were performed for the whole brain on a CT scanner with 0.3 cm slice thickness. The patients were positioned supine, and straight and level. A warm wet sheet of plastic mesh was placed over the face to fit around the head and was

Table 1.1: Evaluation metrics for PTV in terms of D_{MEAN} , D_{max} and D_{min} covered 95% of the target

Patient Code	D_{mean} (Gy)		D_{max} (Gy)		D_{min} (Gy)		$D_{95\%}$ (Gy)	
	3DCRT	IMRT	3DCRT	IMRT	3DCRT	IMRT	3DCRT	IMRT
01	60.00	61.21	64.88	62.36	52.58	53.70	58.10	57.60
02	61.15	60.50	67.18	67.00	54.46	51.70	59.10	57.00
03	60.00	59.75	68.28	64.53	47.52	39.70	56.21	58.29
04	62.00	60.00	64.00	63.80	41.50	44.19	57.40	54.23
05	59.72	60.68	62.53	61.3	56.72	50.09	58.23	59.57
06	60.02	59.32	65.43	64.47	41.87	48.00	59.30	58.00
07	61.00	62.08	63.50	62.50	46.11	46.60	58.11	59.70
08	61.00	59.88	64.63	64.00	49.45	43.60	59.50	58.50
09	63.00	62.00	61.50	60.00	50.60	45.50	58.20	57.50
10	62.53	61.90	60.75	59.45	49.86	44.95	57.80	56.92
Mean	61.04±1.15	60.72±1.00	64.26±2.36	62.95±2.33	49.06±4.98	46.80±4.16	58.20±0.97	57.73±1.55
P-value	P<0.519		P<0.228		P<0.285		P<0.423	

Table 1.2. Evaluation metrics for the PTV in terms of CI, HI and TCI

Patient Code	$CI = \frac{PTV_{95\%PD}}{V_{PTV}}$		$HI = \frac{D_{2\%} - D_{98\%}}{D_{50\%}}$		$TCI = \frac{PTV_{PD}}{PTV}$	
	3DCRT	IMRT	3DCRT	IMRT	3DCRT	IMRT
01	1.00	0.94	0.06	0.16	0.82	0.68
02	0.99	0.98	0.10	0.14	0.85	0.81
03	0.90	0.99	0.17	0.66	0.46	0.37
04	1.00	0.90	0.06	0.21	0.37	0.73
05	1.00	0.99	0.08	0.05	0.57	0.91
06	0.99	1.00	0.08	0.02	0.46	0.46
07	0.98	0.88	0.21	0.13	0.68	0.53
08	0.99	0.99	0.06	0.15	0.43	0.95
09	0.95	0.97	0.07	0.20	0.45	0.09
10	0.99	0.98	0.09	0.15	0.88	0.87
Mean	0.97±0.039	0.96±0.041	0.98±0.050	0.18±0.176	0.59±0.194	0.72±0.0.20
P-value	P<0.481		P<0.165		P<0.143	

secured to the table to ensure that the patient is in the correct position during each treatment session. After the CT scan, the images were transferred to the treatment planning system (TPS) to initiate the planning. Table (1.1) shows the mean, max and minimum dose that covered 95% of the target and p-value of the target (PTV) for both modalities. The prescribed dose was 60 Gy.

3.2. PTV

A statistically significant difference between 3DCRT and IMRT and in the mean dose to the PTV ($p < 0.519$) has been observed. The mean value of the PTV was 61.04 ± 1.152 in 3DCRT and 60.72 ± 1.005 in IMRT. The maximum dose to the PTV in 3DCRT (64.26 ± 2.36) and in IMRT (62.95 ± 2.33) had a lower maximum dose to the PTV ($p = 0.228$). This result indicates that IMRT was better than 3DCRT. The average minimum dose in IMRT was (46.80 ± 3.89) compared to (49.06 ± 4.98) in 3DCRT, ($p = 0.285$). The dose to 95% of the PTV was (57.73 ± 1.55) in IMRT to (58.20 ± 0.97) in 3DCRT, ($p = 0.423$). Conformity index (CI) was approximately equal in both modalities with an average value of 0.962 ± 0.041 in IMRT compared to (0.969 ± 0.039) in 3DCRT, ($p = 0.481$). The average homogeneity index (HI) in IMRT was 0.187 ± 0.176 and 0.099 ± 0.050 in 3DCRT, ($p = 0.165$). Therefore, IMRT achieved an

improvement in HI. Target coverage index (TCI) in IMRT was 0.7213 ± 0.2050 and 0.5970 ± 0.194 in 3DCRT (Table 1.2).

3.3. Isodose distribution and DVH analysis.

Isodose distributions for the IMRT and 3D-CRT are displayed in figure 1 and 2. The 3DCRT plan contained the PTV receiving greater than 108% of the prescription dose, 65.3 Gy. This was not the case in the IMRT plan, as the dose distribution within the PTV was more homogeneous. There were hot spots (doses greater than 63 Gy) in the lateral portion of the PTV in the 3DCRT plan and in the upper portion of the PTV in the IMRT plan. The distributions showed comparable PTV dose coverage between the two modalities. PTV conformity in the 3DCRT plan appeared worse than in IMRT. The 30 Gy lines extended farther to cover the brain in IMRT than in the 3DCRT plan. However, a small region of PTV in the 3DCRT plan was receiving 65 Gy or greater, the PTV dose conformity was greater in the IMRT

DVH provides useful quantitative dose assessment by direct visual inspection of the dose curve [18]. Figure 3 contains a DVH for the 3DCRT and IMRT plans. The y-axis of a DVH, specifically for the PTV, represent the region where the curve bends away from 100% and “falls off” with the curve maintaining a constant slope. The IMRT plan




Figure 1: Isodose distribution of patient Rt. parieto-occipital glioma planned with (A) 3DCRT (B) IMRT.




Figure 2: Isodose distribution of patient Rt. parieto-occipital glioma planned with (A) 3DCRT (B) IMRT.




Figure 3: Cumulative dose volume histogram of patient with postoperative malignant glioma in the right parietal lobe glioma. (A) 3DCRT (B) IMRT.

contained a broader region in the PTV, which indicates higher dose coverage compared with 3DCRT. The PTV had a sharper falloff in the IMRT plan representing the superior PTV dose homogeneity observed in the isodose distributions. DVHs showed a low dose to optic chiasm, optic nerve, left and right lens and left eye in the IMRT plan comparable to that of 3DCRT, and also a low dose to the brain stem, spinal cord, right eye and right optic nerve in IMRT.

Discussion

Patients with cerebral malignant gliomas classified as grade III or IV according to the WHO grading system which account for three-fourths of all glioma cases, were included in this study. Surgery is the first choice of treatment, but because of infiltrative growth and no obvious boundaries with the surrounding normal tissue in higher grade malignant gliomas, coupled with the peculiarity of the anatomical location, complete surgical resection is often difficult if not impossible. Postoperative radiation therapy has been used as conventional treatment for malignant gliomas with the radiation dose generally being 60 Gy, at 1.8–2.0 Gy per fraction. There has been a dramatic improvement in radiotherapy techniques over the last two decades. Improvements in dose distribution and local control have been observed with 3DCRT as compared with conventional two dimensional treatment planning. It has also been showed that the morbidity of therapy decreased with the use of 3DCRT compared with conventional treatment planning. Furthermore, IMRT has shown improvement in target dose conformity, as well as reduction in the dose to the normal tissues while achieving comparable target coverage when compared with 3DCRT techniques in many treatment sites including esophagus, prostate, paranasal sinuses, nasopharynx and other head and neck sites [1,4,8-11].

In case of treatment of malignant glioma with standard therapy consisting of maximal safe surgical resection followed by involved field radiation therapy and chemotherapy has shown survival advantage in favourable prognostic groups. Uncertainties in target volume definition may not only result in marginal misses of tumor but also in unnecessarily overdosing the normal brain. The recent developments in CNS imaging technology like CT and MRI fusion in radiotherapy planning and functional imaging may further increases the ability to more precisely define the

target volume and target the areas at risk of failure. If gliomas can accurately mapped, IMRT may provide further advantage because of its ability to target selected more resistance parts within the tumor with higher radiation doses without increasing the dose to normal tissue. As the number of long term survivors increases, an increase will almost certainly be seen in the number of patients suffering from the late effect of radiation. Therefore to ensure optimal coverage with minimal radiation injury, investigating the integration of advanced, highly conformal radiotherapy techniques for this disease is important. This study was a comparative dosimetric evaluation of IMRT and 3DCRT for treatment of ten patients of malignant glioma, with respect to target coverage, conformity of prescribed dose volume, sparing of organ at risk and integral dose to non-target normal brain tissue.

Comparison of IMRT and 3DCRT for the malignant glioma of the brain are scarce in literature [5,12]. Chan et. al. with a study, group of 5 patients demonstrated that, simultaneous boost in IMRT delivered higher dose to the gross tumor volume while respecting same critical normal tissue constraint and also still maintaining the uninvolved normal brain tissue at dose levels of the 3DCRT . One more study by Narayana et. al. analyzed 20 patients, showed that regardless of tumor location IMRT did not lead to significant improvement in target coverage (maximum dose, minimum dose ,or D95 coverage) when compared to 3DCRT . Our dosimetric analysis confirmed that there was no significant difference in target coverage between IMRT and 3DCRT plans with slight superiority in 3DCRT plan in the range of 95%-100% of prescribed dose. Both techniques were shown good

target coverage in initial PTV and boost PTV. For many gliomas target coverage and dose uniformity are excellent with standard 3DCRT techniques owing to the nearly spherical or cylindrical shape of the lesion. Therefore it was not surprising that significant further improvement was not observed with IMRT. Target coverage and dose uniformity improvement with IMRT have been primarily reported in sights like Head and Neck or Prostate [8, 9], where the target is concave, surrounding normal tissues with dose limits much less than that of the tumor. Gliomas can be highly irregular but typically exhibit few concavities. When concavities do exist such as when the tumors surrounds the chiasm the required dose gradient between tumor and normal tissues is often less than that observed in other sites. As a result very good target coverage is often achieved with 3D planning. However as we

escalate the prescription dose for this tumors even if only to areas of suspected high tumor density, the benefit of IMRT might increase because steeper dose gradients and more concave dose distributions will be necessary. Our study showed almost similar dose uniformity within the target volume both in 3DCRT and IMRT as indicated by high degree of dose uniformity.

Our data are comparable to those reported by Hermanto et. al. where IMRT did not further improve target coverage or dose uniformity within the target, but it did results in statistically significant superiority in target conformity ($p < 0.001$), and also significant reduction in the mean and maximum doses to the critical structures like brain stem, optic pathway ($p < 0.05$). In IMRT if the normal structures like eloquent cortex, brain stem and optic pathway is located near the target, there is actually a compromise to be done in normal tissue sparing and target coverage in the range of 95%-100% of prescribed dose, because if we optimize stringent dose constraint for normal tissue located nearby target it was trying to create cold spot within the target. Dose received by the 50% of the volume of critical normal tissue was improved in IMRT plans compared to 3DCRT plan. The integral dose was evaluated for Brain-PTV, the average normal brain tissue integral dose was reduced in IMRT compared with 3DCRT by approximately 8%. These finding are comparable with majority of the published studies. A study by Hermanto et. al. [25], demonstrated IMRT decreased the total integral dose to the non-target brain tissue by 7%-10%, Narayana et. al. [23], reported a 7% decrease in mean dose to normal brain with IMRT compared with 3DCRT. In our study, 90% of the patients had absolute reduction of integral dose with IMRT and only about 10% of patient showed high integral dose. The reason for this could be in those cases the tumor was located eccentrically in the occipital lobe and this was adequately covered with two fields with 3DCRT techniques, whereas for the treatment of the same target with IMRT multiple fields at different angulations need to be selected. The passage of beams through larger depth might tend to increase the integral dose to non-target brain. It together underscores the fact that with careful IMRT planning integral dose to the normal tissues can be significantly decreased. With careful planning in regard to choice of beam angles, beam weighting, and recognition of potential exposure of normal tissues to exit dose, our study showed that IMRT enabled improvement in target dose conformity, critical tissue sparing, and reduction of integral dose.

This superior dosimetric advantage of IMRT may prove useful in reducing dose to the surrounding critical structures when tumor is situated very close to these structures, in minimizing the treatment related morbidity like cognition deficit, to improve quality of life and also may have an option to re-irradiate for recurrence of tumor when indicated in long time survivors.

Conclusions

In the present study, target dose coverage was improved with IMRT planning as compared with 3D-CRT planning, and dose to normal structures was concomitantly decreased. With careful planning and judicious selection of beam parameters, IMRT improved target conformity and sparing of critical normal tissues, without increasing the integral dose and low-dose volume in patients with high-grade gliomas. New diagnostic and therapeutic tools hold promise for improving outcomes in patients with high-grade glioma. Combining modern tumor imaging technology with IMRT will permit more accurate tumor definition and radiation dose intensification without increasing injury to normal brain and adjacent critical structures. Moreover, in the era of more effective systemic treatments and an increased number of long-term survivors, the use of IMRT may minimize toxicity and improve quality of life.

Conflict of interest: Nil

Source of Funding: Nil

References

1. J Laperrere N, Zuraw L, Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. *Radiother Oncol* 2002;64:259-273.
2. Do V, GebSKI V, Barton MB. The effect of waiting for radiotherapy for grade III/IV gliomas. *Radiother Oncol* 2000;57:131-136.
3. Lrwin C, Hunn M, Purdie G, Hamilton D. Delay in radiotherapy shortens survival in patients with high grade glioma. *Neurooncol* 2007;85:339-343.
4. Tanaka M, Ino Y, Nakagawa K, Tago M, Todo T. High-dose conformal radiotherapy for supratentorial malignant glioma: a historical comparison. *Lancet Oncol* 2005;6:953-960.
5. Tsien C, Moughan J, Michalski JM et. al. Phase I three-dimensional conformal radiation dose escalation study in newly diagnosed glioblastoma. *Radiation Therapy Oncology*

- Group Trial 98-03. *Int J Radiat Oncol Biol Phys* 2009;73:699-708.
6. Souhami L, Seiferheld W, Brachman D et. al. Randomized comparison of stereotactic radiosurgery followed by conventional radiotherapy with carmustine for patients with glioblastoma multiforme : report of Radiation Therapy Oncology Group 93-05 protocol. *Int J Radiat Oncol Biol Phys* 2004;60:853-860.
 7. Ohashi T, Takeda A, Shigematsu N et. al. Does distribution analysis of axillary lymph nodes for three dimensional radiotherapy with a field-in-field technique for breast cancer. *Int J Radiat Oncol Biol Phys* 2009;73:80-87.
 8. Nakamatsu K, Suiuki M, Nishimura Y et. al. Treatment outcome and dose-volume histogram analysis of simultaneous integrated boost method for malignant gliomas using intensity-modulated radiotherapy. *Int J Clin Oncol* 2008;13:48-53.
 9. A, Rakovitch E, Sixel K et. al. Inverse vs. forward breast IMRT Planning. *Med Dosim* 2005;30:149-154.
 10. McDonald SM, Ahmad S, Kachris S et. al. Intensity modulated radiation therapy versus three-dimensional conformal radiation therapy for the treatment of high grade glioma: a dosimetric comparison. *J Appl Clin Med Phys* 2007;8:47-60.
 11. Dogan N, Currine I, Ljoyd R, Bump EA, Arthur DW. Optimized dose coverage of regional lymph nodes in breast cancer: the role of intensity-modulated radiotherapy. *Int Radiat Oncol Biol Phys* 2007;68:1238- 1250.
 12. Sansin N, Berger MS. Gliomas extent of resection and its impact on patient outcome. *Neurosurgery* 2008;62:753-764.
 13. Xia, P., Fu, K. K., Wong, G.W., Akazawa, C. and Verhey, L.J. (2000) Comparison of Treatment Plans Involving Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma. *International Journal of Radiation Oncology, Biology, Physics*, 48, 29-37.
 14. Wu, Q., Manning, M., Schmidt-Ullrich, R. and Mohan, R. (2000) The Potential for Sparing of Parotids and Escalation of Biologically Effective Dose with Intensity-Modulated Radiation Treatments of Head and Neck Cancers: A Treatment Design Study. *International Journal of Radiation Oncology, Biology, Physics*, 46, 195-205.
 15. Tyng, C.J., Chojniak, R., Pinto, P.N.V., Borba1, M.A., Bitencourt, A.G.V., Fogaroli, R.C., Castro, D.G. and Novaes, P.E. (2009) Conformal Radiotherapy for Lung Cancer: Interobservers' Variability in the Definition of Gross Tumor Volume between Radiologists and Radiotherapists. *Radiation Oncology*, 4, 28.
 16. Goyal, S., Cohler, A., Camporeale J., Narra, V. and Yue, N.J. (2008) Intensity-Modulated Radiation Therapy for Orbital Lymphoma. *Radiation Medicine*, 26, 573-581.
 17. Tribius, S. and Bergelt, C. (2011) Intensity-Modulated Radiotherapy versus Conventional and 3D Conformal Radiotherapy in Patients with Head and Neck Cancer: Is There a Worthwhile Quality of Life Gain. *Cancer Treatment Reviews*, 37, 511-519.
 18. Guckenberger, M., Pohl, F., Baier, K., Meyer, J., Vordermark, D. and Flentje, M. (2006) Adverse Effect of a Distended Rectum in Intensity-Modulated Radiotherapy (IMRT) Treatment Planning of Prostate Cancer. *Radiation Oncology*, 79, 59-64.
 19. Van Elmpt, W., Nijsten, S., Mijnheer, B., Dekker, A. and Lambin, P. (2008) The Next Step in Patient-Specific QA: 3D Dose Verification of Conformal and Intensity-Modulated RT Based on EPID Dosimetry and Monte Carlo Dose Calculations. *Radiation Oncology*, 86, 86-92.
 20. H. A. Sharyan1, S. H. Allehyani1 and A. R. Tolba. (2015). Dosimetric Comparison of 3DCRT Versus RapidArc in Terms of Iso-dose Distribution, Dose Volume Histogram (DVH) and Dosimetric Results for the PTV and Critical Organs for Glioblastoma (GBM),5(5):208-219
 21. Kuo, Y. C., Chiu, Y. M., Shih, W. P., Yu, H. W., Chen, C. W., Wong, P. F., and Hwang, J. J.(2011), Volumetric intensity-modulated Arc (RapidArc) therapy for primary hepatocellular carcinoma: comparison with intensity-modulated radiotherapy and 3-D conformal radiotherapy. *Radiation Oncology*, 6: 76.
-
-